NO20024386L - Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer - Google Patents

Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer

Info

Publication number
NO20024386L
NO20024386L NO20024386A NO20024386A NO20024386L NO 20024386 L NO20024386 L NO 20024386L NO 20024386 A NO20024386 A NO 20024386A NO 20024386 A NO20024386 A NO 20024386A NO 20024386 L NO20024386 L NO 20024386L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
NO20024386A
Other languages
English (en)
Other versions
NO20024386D0 (no
Inventor
Dennis Jay Hoover
Ravi Mysore Shanker
Dwayne Thomas Friesen
Douglas Alan Lorenz
James Alan Schrive Nightingale
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20024386D0 publication Critical patent/NO20024386D0/no
Publication of NO20024386L publication Critical patent/NO20024386L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
NO20024386A 2000-03-16 2002-09-13 Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer NO20024386L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
NO20024386D0 NO20024386D0 (no) 2002-09-13
NO20024386L true NO20024386L (no) 2002-11-13

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024386A NO20024386L (no) 2000-03-16 2002-09-13 Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer

Country Status (32)

Country Link
US (1) US20010053778A1 (no)
EP (1) EP1263414A1 (no)
JP (1) JP2003526654A (no)
KR (1) KR20020081445A (no)
CN (1) CN1418089A (no)
AP (1) AP2002002621A0 (no)
AR (1) AR027656A1 (no)
AU (1) AU2001242669A1 (no)
BG (1) BG107037A (no)
BR (1) BR0109189A (no)
CA (1) CA2403241A1 (no)
CO (1) CO5280087A1 (no)
CZ (1) CZ20022955A3 (no)
EA (1) EA200200858A1 (no)
EE (1) EE200200530A (no)
HU (1) HUP0204583A2 (no)
IL (1) IL151320A0 (no)
IS (1) IS6508A (no)
MA (1) MA26882A1 (no)
MX (1) MXPA02009097A (no)
NO (1) NO20024386L (no)
OA (1) OA12232A (no)
PA (1) PA8513601A1 (no)
PE (1) PE20011184A1 (no)
PL (1) PL360780A1 (no)
SK (1) SK12622002A3 (no)
SV (1) SV2002000343A (no)
TN (1) TNSN01040A1 (no)
TR (1) TR200202184T2 (no)
WO (1) WO2001068055A1 (no)
YU (1) YU67202A (no)
ZA (1) ZA200207290B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EA006777B1 (ru) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) * 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
AU2013315619B2 (en) 2012-09-11 2018-02-08 Astellas Pharma Inc. Formulations of enzalutamide
EP3021836B1 (en) 2013-07-19 2020-10-07 Siga Technologies Inc. Amorphous tecovirimat preparation
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3068200B2 (ja) * 1995-06-06 2000-07-24 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ阻害剤としての置換n−(インドール−2−カルボニル−)アミドおよび誘導体
CA2224062C (en) * 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
KR20020081445A (ko) 2002-10-26
BR0109189A (pt) 2003-05-27
PE20011184A1 (es) 2001-11-15
AP2002002621A0 (en) 2002-09-30
TNSN01040A1 (fr) 2005-11-10
IL151320A0 (en) 2003-04-10
MA26882A1 (fr) 2004-12-20
OA12232A (en) 2006-05-10
WO2001068055A1 (en) 2001-09-20
SK12622002A3 (sk) 2004-02-03
AR027656A1 (es) 2003-04-09
CN1418089A (zh) 2003-05-14
ZA200207290B (en) 2003-09-11
NO20024386D0 (no) 2002-09-13
HUP0204583A2 (hu) 2003-04-28
IS6508A (is) 2002-08-16
EA200200858A1 (ru) 2003-02-27
EP1263414A1 (en) 2002-12-11
MXPA02009097A (es) 2003-03-12
SV2002000343A (es) 2002-07-03
PL360780A1 (en) 2004-09-20
AU2001242669A1 (en) 2001-09-24
JP2003526654A (ja) 2003-09-09
PA8513601A1 (es) 2004-08-31
BG107037A (bg) 2003-04-30
CA2403241A1 (en) 2001-09-20
EE200200530A (et) 2004-04-15
CO5280087A1 (es) 2003-05-30
CZ20022955A3 (cs) 2003-09-17
US20010053778A1 (en) 2001-12-20
YU67202A (sh) 2006-01-16
TR200202184T2 (tr) 2003-01-21

Similar Documents

Publication Publication Date Title
NO20024386D0 (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
NO20030506D0 (no) Farmasöytiske sammensetninger av kolesterylesteroverföringsproteininhibitorer
HU0101158D0 (en) Use of glycogen phosphorylase inhibitors
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
FI20001750A0 (fi) Farmaseuttisia koostumuksia
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
HUP0400327A3 (en) Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
EE05585B1 (et) Indasoolihendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ning nende kasutamine
SG155229A1 (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20043902L (no) Kontrollert syntese av ziprasidon og sammensetninger derav
EE05020B1 (et) Glburiidi ravimkoostis
NO20014893L (no) Farmasoytiske sammensetninger av erythropoietin
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
EE200300589A (et) Ravimkoostised
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
IS7435A (is) Indólamíðafleiður sem búa yfir tálmavirkni gegn glýkógenfosfórýlasa
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
IL159085A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application